drugset / Trial / NCT02580994
Pembrolizumab in Untreated Extensive SCLC
Phase 2
Completed
125 enrolled
European Organisation for Research and Treatment of Cancer - EORTC
Merck Sharp & Dohme LLC · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
Timeline
- Start
- 2017-12-08
- Primary completion
- 2020-09-22
- Completion
- 2022-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |